DC-LYMPH

The Role of Lymphatic Vessels in Dendritic Cell Homing and Maturation

 Coordinatore ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Switzerland [CH]
 Totale costo 1˙730˙966 €
 EC contributo 1˙730˙966 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2007-StG
 Funding Scheme ERC-SG
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-05-01   -   2013-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

 Organization address address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015

contact info
Titolo: Dr.
Nome: Luciana
Cognome: Vaccaro
Email: send email
Telefono: +41 21 693 5582
Fax: +41 21 693 5583

CH (LAUSANNE) hostInstitution 0.00
2    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

 Organization address address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015

contact info
Titolo: Prof.
Nome: Melody A.
Cognome: Swartz
Email: send email
Telefono: +41 21 693 9686
Fax: +41 21 693 9670

CH (LAUSANNE) hostInstitution 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

flow    lymphedema    vessels    activation    toward    regarding    immune    lymphatics    alter    migration    examine    dc    cell    critical    therapeutic    immunomodulation    strategies    mechanisms    homing    lymphatic    biophysical    dcs    vessel    entry    function   

 Obiettivo del progetto (Objective)

'Dendritic cell (DC) activation and homing from the periphery to lymph nodes is a critical first event in the immune response. It involves upregulation of the chemokine receptor CCR7 and chemoinvasion towards lymphatic vessels. Despite its critical importance in adaptive immunity, the mechanisms of DC migration towards and entry into lymphatics are still poorly understood; this severely limits new therapeutic strategies for immunomodulation and even strategies for treating lymphedema, which is exacerbated by poor immune functioning. We propose a battery of physiological, cell-biological, molecular, and computational studies to determine both the mechanisms of DC homing to lymphatic vessels and how DCs modulate lymphatic function. We approach this from the perspectives of both the DC and the lymphatic vessel. Regarding the DC, we will examine computationally and experimentally how draining flows toward the lymphatic alter their migration tactics and test our hypothesis that DCs possess a biomolecular flow-detector network (which we refer to as autologous chemotaxis) and are thus able to sense the direction of the subtle flow of fluid toward the lymphatics. Regarding the lymphatic vessel, we will elucidate how biochemical and biophysical inflammatory signals regulate their drainage function, alter cell-cell adhesions and overall permeability, and alter adhesion receptors to facilitate DC homing and entry. Finally, we will examine DC migration in mice with dysfunctional lymphatics and explore strategies to improve immune response. These will be carried out in 4 main projects, and will complement our recent work in lymphatic functional biology as well as our more therapeutic investigations in DC targeting and activation (Reddy et al., Nature Biotechnol., 2007). This deeper knowledge of mechanisms of DC-lymphatic cross-talk in a relevant biophysical context will enable our long-term goal of rational design for therapeutic immunomodulation and lymphedema.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

CSV (2013)

"Conflict, Strategies, and Violence: An Actor-based Approach to Violent and Non-Violent Interactions"

Read More  

GLUCOSE SENSING (2012)

Transcriptional networks in glucose sensing

Read More  

MUMID (2010)

"Multimodal tools for Molecular Imaging, Diagnostics and Therapeutics"

Read More